AUPH Aurinia Pharmaceuticals Inc
Price (delayed)
$8.215
Market cap
$1.13B
P/E Ratio
205.38
Dividend/share
N/A
EPS
$0.04
Enterprise value
$1.12B
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The
Highlights
Aurinia Pharmaceuticals's EPS has surged by 129% QoQ and by 107% YoY
The net income has soared by 126% from the previous quarter and by 107% YoY
The quick ratio has declined by 18% since the previous quarter and by 17% year-on-year
The gross margin has declined by 4.2% year-on-year
Key stats
What are the main financial stats of AUPH
Market
Valuations
Earnings
Shares outstanding
137.34M
Market cap
$1.13B
Enterprise value
$1.12B
Price to earnings (P/E)
205.38
Price to book (P/B)
3.12
Price to sales (P/S)
5
EV/EBIT
91.52
EV/EBITDA
35.43
EV/Sales
4.78
Revenue
$235.13M
Gross profit
$206.89M
Operating income
-$4.69M
Net income
$5.75M
EBIT
$12.28M
EBITDA
$31.73M
Free cash flow
$44.11M
Per share
Balance sheet
Liquidity
EPS
$0.04
EPS diluted
$0.04
Free cash flow per share
$0.31
Book value per share
$2.64
Revenue per share
$1.64
TBVPS
$3.82
Total assets
$550.65M
Total liabilities
$173.17M
Debt
$79.37M
Equity
$377.48M
Working capital
$348.83M
Debt to equity
0.21
Current ratio
4.57
Quick ratio
4.04
Net debt/EBITDA
-0.13
Margins
Efficiency
Dividend
EBITDA margin
13.5%
Gross margin
88%
Net margin
2.4%
Operating margin
-2%
Return on assets
1.1%
Return on equity
1.5%
Return on invested capital
2.6%
Return on capital employed
2.7%
Return on sales
5.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AUPH stock price
How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
0.8%
1 week
0.31%
1 month
3.07%
1 year
56.48%
YTD
-8.52%
QTD
-8.52%
Financial performance
How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$235.13M
Gross profit
$206.89M
Operating income
-$4.69M
Net income
$5.75M
Gross margin
88%
Net margin
2.4%
The net income has soared by 126% from the previous quarter and by 107% YoY
Aurinia Pharmaceuticals's net margin has surged by 124% QoQ and by 105% YoY
The operating margin has soared by 96% YoY and by 86% from the previous quarter
The operating income has soared by 95% year-on-year and by 86% since the previous quarter
Growth
What is Aurinia Pharmaceuticals's growth rate over time
Valuation
What is Aurinia Pharmaceuticals stock price valuation
P/E
205.38
P/B
3.12
P/S
5
EV/EBIT
91.52
EV/EBITDA
35.43
EV/Sales
4.78
Aurinia Pharmaceuticals's EPS has surged by 129% QoQ and by 107% YoY
The price to book (P/B) is 25% lower than the 5-year quarterly average of 4.1 but 19% higher than the last 4 quarters average of 2.6
AUPH's equity is down by 2.7% since the previous quarter
The stock's P/S is 100% less than its 5-year quarterly average of 1329.1 but 10% more than its last 4 quarters average of 4.5
The revenue has increased by 34% YoY and by 7% from the previous quarter
Efficiency
How efficient is Aurinia Pharmaceuticals business performance
AUPH's ROIC has soared by 187% since the previous quarter and by 116% year-on-year
Aurinia Pharmaceuticals's return on sales has surged by 175% QoQ and by 112% YoY
The company's return on assets has surged by 126% QoQ and by 107% YoY
The ROE has soared by 125% from the previous quarter and by 107% YoY
Dividends
What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AUPH.
Financial health
How did Aurinia Pharmaceuticals financials performed over time
Aurinia Pharmaceuticals's current ratio has decreased by 18% from the previous quarter and by 17% YoY
The quick ratio has declined by 18% since the previous quarter and by 17% year-on-year
Aurinia Pharmaceuticals's debt is 79% lower than its equity
Aurinia Pharmaceuticals's debt has decreased by 19% YoY and by 10% QoQ
The company's debt to equity fell by 19% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.